Ran Cheng

This paper identifies a novel non-canonical RT-loop degron in VAV1 and demonstrates how conformational restriction and computational modeling enhance molecular glue potency for proteasomal degradation.

This study develops LD5095, a novel cereblon-recruiting RIPK1 degrader, showing potent RIPK1 degradation and tumor sensitization to immune checkpoint inhibitors.

This paper develops and characterizes PSIRC3, a covalent PROTAC for BTK, showing it achieves potent degradation with sub-nanomolar potency and high selectivity, challenging the necessity of catalytic turnover for PROTAC efficacy.

This study designs and evaluates a novel RIPK1 degrader, LD5097, showing potent degradation activity, favorable pharmacokinetics, and enhanced antitumor effects in cancer models.

This study introduces lysineless HiBiT-RR and nLucK0 tagging systems to reduce degradation artifacts in monitoring protein degradation, showing HiBiT-RR retains sensitivity and nLucK0 shows different degradation patterns than nLucWT.